HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas.

Abstract
The MAGE gene is selectively expressed in cancer tissues such as melanoma or gastrointestinal carcinomas, whereas no expression is observed in normal tissues except testis. There are several reports of successful induction of HLA class I-restricted antitumor CTLs using MAGE peptides, and some clinical trials with these immunogenic peptides were reported as effective for some patients with malignant melanoma. However, there are no similar studies in gastrointestinal carcinomas, which are important neoplasms. Autologous dendritic cells (DCs) were generated ex vivo and were pulsed with MAGE-3 peptide, depending on the patient's HLA haplotype (HLA-A2 or A24). Patients were immunized with DC pulsed with MAGE-3 peptide every 3 weeks at four times. Twelve patients with advanced gastrointestinal carcinoma (six stomach, three esophagus, and three colon) were treated, and no toxic side effects were observed. Peptide-specific CTL responses after vaccination were observed in four of eight patients. Improvement in performance status was recognized in four patients. Tumor markers decreased in seven patients. In addition, minor tumor regressions evidenced by imaging studies were seen in three patients. These results suggested that DC vaccination with MAGE-3 peptide is a safe and promising approach in the treatment of gastrointestinal carcinomas.
AuthorsN Sadanaga, H Nagashima, K Mashino, K Tahara, H Yamaguchi, M Ohta, T Fujie, F Tanaka, H Inoue, K Takesako, T Akiyoshi, M Mori
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 7 Issue 8 Pg. 2277-84 (Aug 2001) ISSN: 1078-0432 [Print] United States
PMID11489802 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, Neoplasm
  • CA-19-9 Antigen
  • Cancer Vaccines
  • Carcinoembryonic Antigen
  • MAGEA3 protein, human
  • Neoplasm Proteins
  • Serpins
  • squamous cell carcinoma-related antigen
Topics
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm (analysis)
  • CA-19-9 Antigen (analysis)
  • Cancer Vaccines (immunology)
  • Carcinoembryonic Antigen (analysis)
  • Cytotoxicity, Immunologic
  • Dendritic Cells (immunology)
  • Female
  • Gastrointestinal Neoplasms (immunology, metabolism, prevention & control)
  • Humans
  • Immunohistochemistry
  • Immunotherapy, Adoptive
  • Male
  • Middle Aged
  • Neoplasm Proteins (immunology)
  • Serpins
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: